Identifying microRNA/mRNA dysregulations in ovarian cancer

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Miles, Gregory D ^a,b   Seiler, Michael ^c   Rodriguez, Lorna ^a   Rajagopal, Gunaretnam ^a,d   Bhanot, Gyan ^a,b,c,d  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b BOSTON UNIVERSITY   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d INSTITUTE FOR ADVANCED STUDY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; E2F3 PROTEIN, HUMAN; GLUTAMATE CYSTEINE LIGASE; MESSENGER RNA; MICRORNA; MIRN133 MICRORNA, HUMAN; MIRN139 MICRORNA, HUMAN; MIRN140 MICRORNA, HUMAN; MIRN145 MICRORNA, HUMAN; RAD51AP1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR E2F3; TUMOR ANTIGEN;

ARTICLE; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; OVARY TUMOR;

ANTIGENS, NEOPLASM; CLUSTER ANALYSIS; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; E2F3 TRANSCRIPTION FACTOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMATE-CYSTEINE LIGASE; HUMANS; MICRORNAS; OVARIAN NEOPLASMS; RNA, MESSENGER;

EID: 84858859368     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-164     Document Type: Article

References (39)

1. Society AC, Cancer Facts & Figures 2010 Atlanta: American Cancer Society 2010 22472509
2. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. Siegel R, Ward E, Brawley O, Jemal A, CA: a cancer journal for clinicians 2011 61 4 212 236 10.3322/caac.20121
3. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008 455 7216 1061 1068 10.1038/nature07385 18772890
4. Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma. Liu H, Brannon AR, Reddy AR, Alexe G, Seiler MW, Arreola A, Oza JH, Yao M, Juan D, Liou LS, et al. BMC Syst Biol 2010 4 51 10.1186/1752-0509-4-51 20420713
5. MicroRNA signatures in human ovarian cancer. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et al. Cancer Res 2007 67 18 8699 8707 10.1158/0008-5472.CAN-07-1936 17875710 (Pubitemid 47437445)
6. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih Ie M, Zhang Y, Wood W, Becker KG, Morin PJ, PLoS One 2008 3 6 2436 10.1371/journal.pone.0002436 18560586
7. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, et al. Cancer Res 2008 68 2 425 433 10.1158/0008-5472.CAN-07-2488 18199536 (Pubitemid 351380068)
8. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K, et al. Proc Natl Acad Sci USA 2008 105 19 7004 7009 10.1073/pnas.0801615105 18458333 (Pubitemid 351754520)
9. MicroRNA expression profiles in serous ovarian carcinoma. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, Kim JW, Kim S, Clin Cancer Res 2008 14 9 2690 2695 10.1158/1078-0432.CCR-07-1731 18451233
10. Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. Wyman SK, Parkin RK, Mitchell PS, Fritz BR, O'Briant K, Godwin AK, Urban N, Drescher CW, Knudsen BS, Tewari M, PLoS One 2009 4 4 5311 10.1371/journal.pone.0005311 19390579
11. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Laios A, O'Toole S, Flavin R, Martin C, Kelly L, Ring M, Finn SP, Barrett C, Loda M, Gleeson N, et al. Mol Cancer 2008 7 35 10.1186/1476-4598-7-35 18442408 (Pubitemid 351699620)
12. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, Murphy S, Dressman HK, Febbo PG, West M, et al. Clin Cancer Res 2005 11 10 3686 3696 10.1158/1078-0432.CCR-04-2398 15897565 (Pubitemid 40685585)
13. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI, et al. Clin Cancer Res 2005 11 6 2149 2155 10.1158/1078-0432.CCR-04-1673 15788660 (Pubitemid 40490171)
14. Gene expression patterns that characterize advanced stage serous ovarian cancers. Lancaster JM, Dressman HK, Whitaker RS, Havrilesky L, Gray J, Marks JR, Nevins JR, Berchuck A, J Soc Gynecol Investig 2004 11 1 51 59 10.1016/j.jsgi.2003.07.004 14706684 (Pubitemid 38050192)
15. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, Libermann TA, Cannistra SA, J Clin Oncol 2004 22 23 4700 4710 10.1200/JCO.2004.04.070 15505275 (Pubitemid 41185079)
16. Some Methods for classification and Analysis of Multivariate Observations. MacQueen JB, Proceedings of 5-th Berkeley Symposium on Mathematical Statistics and Probability Berkeley, University of California Press 1967 1 281 297
17. On Lines and Planes of Closest Fit to Systems of Points in Space. Pearson K, Philosophical Magazine 1901 2 6 559 572
18. ConsensusCluster: a software tool for unsupervised cluster discovery in numerical data. Seiler M, Huang CC, Szalma S, Bhanot G, OMICS 2010 14 1 109 113 10.1089/omi.2009.0083 20141333
19. Identification of a proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma. Rosty C, Sheffer M, Tsafrir D, Stransky N, Tsafrir I, Peter M, de Cremoux P, de La Rochefordiere A, Salmon R, Dorval T, et al. Oncogene 2005 24 47 7094 7104 10.1038/sj.onc.1208854 16007141 (Pubitemid 41573638)
20. HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells. Wilson CA, Cajulis EE, Green JL, Olsen TM, Chung YA, Damore MA, Dering J, Calzone FJ, Slamon DJ, Breast Cancer Res 2005 7 6 1058 R1079 10.1186/bcr1343 16457687
21. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Macleod K, Mullen P, Sewell J, Rabiasz G, Lawrie S, Miller E, Smyth JF, Langdon SP, Cancer Res 2005 65 15 6789 6800 10.1158/0008-5472.CAN-04-2684 16061661 (Pubitemid 41060717)
22. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Ye D, Mendelsohn J, Fan Z, Oncogene 1999 18 3 731 738 10.1038/sj.onc.1202319 9989823 (Pubitemid 29080330)
23. Cell cycle genes as targets of retinoid induced ovarian tumor cell growth suppression. Zhang D, Vuocolo S, Masciullo V, Sava T, Giordano A, Soprano DR, Soprano KJ, Oncogene 2001 20 55 7935 7944 10.1038/sj.onc.1204971 11753676 (Pubitemid 34001554)
24. Ovarian cancer cells that coexpress endogenous Rb and p16 are insensitive to overexpression of functional p16 protein. Todd MC, Sclafani RA, Langan TA, Oncogene 2000 19 2 258 264 10.1038/sj.onc.1203289 10645004 (Pubitemid 30077222)
25. Endogenous human CaMKII inhibitory protein suppresses tumor growth by inducing cell cycle arrest and apoptosis through down-regulation of the phosphatidylinositide 3-kinase/Akt/HDM2 pathway. Ma S, Yang Y, Wang C, Hui N, Gu L, Zhong H, Cai Z, Wang Q, Zhang Q, Li N, et al. J Biol Chem 2009 284 37 24773 24782 10.1074/jbc.M109.028621 19586909
26. Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Masamha CP, Benbrook DM, Cancer Res 2009 69 16 6565 6572 10.1158/0008-5472.CAN-09-0913 19638577
27. EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. Selvendiran K, Tong L, Vishwanath S, Bratasz A, Trigg NJ, Kutala VK, Hideg K, Kuppusamy P, J Biol Chem 2007 282 39 28609 28618 10.1074/jbc.M703796200 17684018 (Pubitemid 47606012)
28. p27(Kip1) stabilization and G(1) arrest by 1,25-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase. Li P, Li C, Zhao X, Zhang X, Nicosia SV, Bai W, J Biol Chem 2004 279 24 25260 25267 10.1074/jbc.M311052200 15075339 (Pubitemid 38756778)
29. E2f3 is critical for normal cellular proliferation. Humbert PO, Verona R, Trimarchi JM, Rogers C, Dandapani S, Lees JA, Genes Dev 2000 14 6 690 703 10733529 (Pubitemid 30176823)
30. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, et al. Clin Cancer Res 2004 10 10 3291 3300 10.1158/1078-0432.CCR- 03-0409 15161682 (Pubitemid 38685433)
31. Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy. Chekerov R, Klaman I, Zafrakas M, Konsgen D, Mustea A, Petschke B, Lichtenegger W, Sehouli J, Dahl E, Neoplasia 2006 8 1 38 45 10.1593/neo.05580 16533424
32. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME, Proc Natl Acad Sci USA 1992 89 7 3070 3074 10.1073/pnas.89.7.3070 1348364
33. Glutamate-cysteine ligase attenuates TNF-induced mitochondrial injury and apoptosis. Botta D, Franklin CC, White CC, Krejsa CM, Dabrowski MJ, Pierce RH, Fausto N, Kavanagh TJ, Free Radic Biol Med 2004 37 5 632 642 10.1016/j.freeradbiomed.2004.05.027 15288121 (Pubitemid 38996790)
34. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC, Cancer research 1998 58 23 5315 5320 9850056 (Pubitemid 28551107)
35. Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis. Dan HC, Jiang K, Coppola D, Hamilton A, Nicosia SV, Sebti SM, Cheng JQ, Oncogene 2004 23 3 706 715 10.1038/sj.onc.1207171 14737105 (Pubitemid 38241271)
36. NuSAP, a novel microtubule-associated protein involved in mitotic spindle organization. Raemaekers T, Ribbeck K, Beaudouin J, Annaert W, Van Camp M, Stockmans I, Smets N, Bouillon R, Ellenberg J, Carmeliet G, J Cell Biol 2003 162 6 1017 1029 10.1083/jcb.200302129 12963707 (Pubitemid 37174185)
37. Phosphorylation and activation of human cdc25-C by cdc2-cyclin B and its involvement in the self-amplification of MPF at mitosis. Hoffmann I, Clarke PR, Marcote MJ, Karsenti E, Draetta G, Embo J 1993 12 1 53 63 8428594 (Pubitemid 23042382)
38. Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway. Arafa el SA, Zhu Q, Barakat BM, Wani G, Zhao Q, El-Mahdy MA, Wani AA, Cancer research 2009 69 23 8910 8917 10.1158/0008-5472.CAN-09-1543 19903849
39. Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Donninger H, Bonome T, Radonovich M, Pise-Masison CA, Brady J, Shih JH, Barrett JC, Birrer MJ, Oncogene 2004 23 49 8065 8077 10.1038/sj.onc.1207959 15361855 (Pubitemid 39531847)